Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima, et al.
Allergy (2019) Vol. 75, Iss. 5, pp. 1188-1204
Open Access | Times Cited: 328

Showing 51-75 of 328 citing articles:

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
Mario Castro, Alberto Papi, Celeste Porsbjerg, et al.
The Lancet Respiratory Medicine (2025)
Closed Access | Times Cited: 1
Bullous pemphigoid
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease
Dimitrios Toumpanakis, Κonstantinos Bartziokas, Agamemnon Bakakos, et al.
Pulmonary Therapy (2025)
Open Access | Times Cited: 1
IL-13 is a driver of COVID-19 severity
Alexandra N. Donlan, Tara E. Sutherland, Chelsea Marie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 61
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
Martin Desrosiers, Leda P. Mannent, Nikhil Amin, et al.
Rhinology Journal (2021)
Open Access | Times Cited: 53
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
Jonathan Corren, Sarbjit S. Saini, Rémi Gagnon, et al.
Journal of Asthma and Allergy (2021) Vol. Volume 14, pp. 1045-1063
Open Access | Times Cited: 50
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Ashish Bansal, Eric L. Simpson, Amy S. Paller, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 1, pp. 101-115
Open Access | Times Cited: 42
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
Amy S. Paller, Lisa A. Beck, Andrew Blauvelt, et al.
Pediatric Dermatology (2022) Vol. 39, Iss. 2, pp. 187-196
Open Access | Times Cited: 37
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Keywan Mortezaee, Jamal Majidpoor
Cellular Oncology (2022) Vol. 45, Iss. 3, pp. 333-353
Closed Access | Times Cited: 37
Role of Basophils in a Broad Spectrum of Disorders
Kensuke Miyake, Junya Ito, Hajime Karasuyama
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
Elena Cantone, Eugenio De Corso, Filippo Ricciardiello, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 8, pp. 1215-1215
Open Access | Times Cited: 35
Dupilumab (Dupixent®) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany
Florian Jansen, Benjamin Becker, Jördis Kristin Eden, et al.
European Archives of Oto-Rhino-Laryngology (2022) Vol. 280, Iss. 4, pp. 1741-1755
Open Access | Times Cited: 31
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma
Lawrence Sher, Michael E. Wechsler, Klaus F. Rabe, et al.
CHEST Journal (2022) Vol. 162, Iss. 1, pp. 46-55
Closed Access | Times Cited: 30
A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis
Maddalena Napolitano, Gabriella Fabbrocini, Luca Potestio, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 8
Closed Access | Times Cited: 30
Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Fabio S. Ryser, Ayla Yalamanoglu, Alan Valaperti, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2712-2723
Open Access | Times Cited: 18
Severe Asthma and Biological Therapies: Now and the Future
Olaia Sardón, Carolina Díaz‐García, Paula Corcuera, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 5846-5846
Open Access | Times Cited: 18
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis
Anju T. Peters, Martin Wagenmann, Jonathan A. Bernstein, et al.
Allergy and Asthma Proceedings (2023) Vol. 44, Iss. 4, pp. 265-274
Open Access | Times Cited: 17
Association between hidradenitis suppurativa and atopic diseases: a multi-center, propensity-score-matched cohort study
Hui‐Chin Chang, Chenyu Lin, Yuchen Guo, et al.
International Journal of Medical Sciences (2023) Vol. 21, Iss. 2, pp. 299-305
Open Access | Times Cited: 17
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
Amy S. Paller, Andreas Pinter, Lara Wine Lee, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1046-1061
Open Access | Times Cited: 7
Wogonoside Ameliorates Airway Inflammation and Mucus Hypersecretion via NF-κB/STAT6 Signaling in Ovalbumin-Induced Murine Acute Asthma
Xiu Yu, Bicheng Cai, Li Yu, et al.
Journal of Agricultural and Food Chemistry (2024) Vol. 72, Iss. 13, pp. 7033-7042
Closed Access | Times Cited: 7
A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
Mingyue Wang, Xing‐Hua Gao, Li Zhang
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 941-951
Open Access | Times Cited: 7
Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Eric L. Simpson, B. Lockshin, Lara Wine Lee, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 1, pp. 261-270
Open Access | Times Cited: 6
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 2, pp. 163-173
Open Access | Times Cited: 6
Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis
Charlie Bridgewood, Darren J. Newton, Nicola Luigi Bragazzi, et al.
Seminars in Immunology (2021) Vol. 58, pp. 101520-101520
Closed Access | Times Cited: 36
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
Daniel J. Jackson, Leonard B. Bacharier, Wanda Phipatanakul, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 1, pp. 44-51.e4
Open Access | Times Cited: 16

Scroll to top